Use case · Target identification & prioritization

Decide which targets to advance, with evidence you can defend

Causaly brings together the genetics, disease biology, safety and competitive evidence behind each target, so your team can rank candidates and show exactly why.

Why it matters

Target decisions set the course of a program

A target chosen on partial evidence can cost years. Identifying candidates broadly, then assessing each one on the same criteria with the counter-evidence in view, gives teams a ranking they can explain.

Identify, then assess

Start broad to find candidate targets for a disease, then assess the shortlist in depth. Causaly supports both steps and keeps them distinct.

The same criteria for every target

Genetic support, disease biology, tractability, safety and competition are assessed the same way, so targets can be compared fairly.

A dossier, not just an answer

Each assessment comes back as a structured, cited report with supporting and contradicting evidence and the gaps still to close.

What it is

What is target identification and prioritization with Causaly?

It means finding, assessing and ranking drug targets using cited evidence. Agentic Research and Scientific Workflows gather the genetics, disease biology, safety signals and competitive activity behind each target, so your team can see why one target ranks above another.

Target identification finds candidate targets for a disease. Target assessment tests each candidate in depth. To examine the link between one target and one disease, see target–disease association.

648M+

scientific relationships across Bio Graph and Pipeline Graph

40M+

biomedical publications and preprints

550K

clinical trial records

225K

GWAS variants with gene context

Indexed content as of October 2026. New literature reaches Bio Graph within about four weeks of publication.

How it works

How Causaly helps you identify and rank targets

Ask Agentic Research for candidate targets in a disease, then run library workflows on the shortlist to build a cited dossier for each one.

  • Identify

    Candidate targets for a disease

    Ask which genes and proteins are implicated in a disease, with Bio Graph relationships, GWAS evidence and Open Targets associations behind each one.

  • Assess

    Each target against the same criteria

    Target Biology Profile, Target-Disease Evidence Assessment and Target Safety Profile cover biology, disease linkage and safety, with tractability from Open Targets.

  • Compare

    Supporting and contradicting evidence, side by side

    Gaps are called out, and Pipeline Graph shows which targets are already crowded with drug programs.

  • Decide

    A dossier your team can defend

    Workflow reports keep a record of each run. Ask follow-up questions, export to Word, PDF or PowerPoint, and rerun the method on the next target.

Key capabilities

What your team can assess for each target

Each part of a target decision has its own evidence. Causaly covers the main ones in one place, with library workflows for the assessments teams run most often.

Target biology

The Target Biology Profile workflow covers a target’s identity, function, disease relevance and risks, with every statement cited.

Target–disease evidence

The Target-Disease Evidence Assessment workflow scores how strongly a target is linked to a disease and gives a recommendation you can trace to the papers.

Target safety

The Target Safety Profile workflow assesses safety risks, the evidence and mechanisms behind them, and mitigation priorities.

Human genetics and tractability

GWAS evidence with gene context, plus connected sources such as Open Targets for tractability and gnomAD for loss-of-function constraint.

Competitive landscape

Pipeline Graph shows which drugs are in development against a target, and its landscape view appears directly inside Agentic Research answers.

From shortlist to the lab

The Pathway and Systems Biology Assessment, Animal Model Selection and Target Assay Selection workflows help plan how to test the targets you shortlist.

Optional: connect internal data through the Enterprise Data Fabric or your own MCP connectors, so your team’s findings are read alongside the public evidence.

“I love how Causaly’s functionality allows me to generate hypotheses and gain inspiration whilst doing research, e.g. while exploring which tissues or cells are affected.”
Senior Scientist · Top 20 pharma

Target identification and prioritization: common questions

How is target identification different from target assessment?

Target identification finds candidate targets for a disease from genetic, biological and literature evidence. Target assessment examines each candidate in depth, covering biology, disease linkage, tractability, safety and competition, so the shortlist can be ranked.

Which data sources does Causaly use to assess a target?

Bio Graph and Pipeline Graph (648M+ scientific relationships), more than 40 million publications and preprints, 550,000 clinical trial records and 225,000 GWAS variants with gene context. Connected sources include Open Targets, STRING, gnomAD, ClinVar, cBioPortal and TCGA.

How does Causaly work with Open Targets?

Open Targets is one of the sources Causaly connects to for target–disease evidence and tractability. Causaly combines it with literature-derived relationships, safety evidence and pipeline data, and reasons across all of them with citations.

How can I check that the answers are accurate?

Every claim links to its source, and citations are validated against the documents actually retrieved. Supporting and contradicting evidence appear side by side, so your scientists can judge the evidence for themselves.

Can Causaly use our internal data?

Yes, as an option. Internal documents can be connected through the Enterprise Data Fabric, and your own MCP connectors can be added to Agentic Research. Causaly does not use customer data to train models.

Bring a disease and a shortlist your team is weighing

We’ll assess the targets with you and walk through the evidence for and against each one.